ArticleJournal of cellular and molecular medicine2012
Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction.
Article in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Injectable hydrogel-based combination therapy for myocardial infarction: a systematic review and Meta-analysis of preclinical trials.BMC cardiovascular disorders · 2024Pooled it
- Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction.Materials today. Bio · 2024Review
- Hydrogels for Cardio and Vascular Tissue Repair and Regeneration.Gels (Basel, Switzerland) · 2024Review
- The Utilisation of Hydrogels for iPSC-Cardiomyocyte Research.International journal of molecular sciences · 2023Review
- A deep dive into the darning effects of biomaterials in infarct myocardium: current advances and future perspectives.Heart failure reviews · 2022Review
- Biomaterials-based Approaches for Cardiac Regeneration.Korean circulation journal · 2021Review
- Biodegradable nanofibrous temperature-responsive gelling microspheres for heart regeneration.Advanced functional materials · 2020Article
- Tissue Engineering and Regenerative Medicine: Achievements, Future, and Sustainability in Asia.Frontiers in bioengineering and biotechnology · 2020Review
- Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases.International journal of nanomedicine · 2018Review
- Heart Repair Using Nanogel-Encapsulated Human Cardiac Stem Cells in Mice and Pigs with Myocardial Infarction.ACS nano · 2017Article
- Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy.Current treatment options in cardiovascular medicine · 2017Review
- The Diverse Roles of Hydrogel Mechanics in Injectable Stem Cell Transplantation.Current opinion in chemical engineering · 2017Article
- Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction.Nature communications · 2016Article
- Nanomaterials for Cardiac Myocyte Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2016Review
- Injectable Hydrogels for Cardiac Tissue Repair after Myocardial Infarction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2015Article
- Improving survival and efficacy of pluripotent stem cell-derived cardiac grafts.Journal of cellular and molecular medicine · 2013Review
- Real-time tracking of adipose tissue-derived stem cells with injectable scaffolds in the infarcted heart.Heart and vessels · 2013Article
- Stem cell-based tissue engineering approaches for musculoskeletal regeneration.Current pharmaceutical design · 2013Review
- Embryonic stem cells for severe heart failure: why and how?Journal of cardiovascular translational research · 2012Review
- Building bridges: leveraging interdisciplinary collaborations in the development of biomaterials to meet clinical needs.Advanced materials (Deerfield Beach, Fla.) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
In this study, an injectable, biodegradable hydrogel composite of oligo[poly(ethylene glycol) fumarate] (OPF) was investigated as a carrier of mouse embryonic stem cells (mESCs) for the treatment of myocardial infarction (MI). The OPF hydrogels were used to encapsulate mESCs. The cell differentiation in vitro over 14 days was determined via immunohistochemical examination. Then, mESCs encapsulated in OPF hydrogels were injected into the LV wall of a rat MI model. Detailed histological analysis and echocardiography were used to determine the structural and functional consequences after 4 weeks of transplantation. With ascorbic acid induction, mESCs could differentiate into cardiomyocytes and other cell types in all three lineages in the OPF hydrogel. After transplantation, both the 24-hr cell retention and 4-week graft size were significantly greater in the OPF + ESC group than that of the PBS + ESC group (P < 0.01). Four weeks after transplantation, OPF hydrogel alone significantly reduced the infarct size and collagen deposition and improved the cardiac function. The heart function and revascularization improved significantly, while the infarct size and fibrotic area decreased significantly in the OPF + ESC group compared with that of the PBS + ESC, OPF and PBS groups (P < 0.01). All treatments had significantly reduced MMP2 and MMP9 protein levels compared to the PBS control group, and the OPF + ESC group decreased most by Western blotting. Transplanted mESCs expressed cardiovascular markers. This study suggests the potential of a method for heart regeneration involving OPF hydrogels for stem cell encapsulation and transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.